Guidelines for Fluoroquinolone Use in Pediatric Patients
Introduction to Fluoroquinolone Use
- The American Academy of Pediatrics recommends that fluoroquinolones should be restricted in pediatric patients to situations where there is no safe and effective alternative to treat an infection caused by multidrug-resistant bacteria or when oral therapy is needed but no other effective oral agent is available 1, 2
Approved Indications for Pediatric Use
- FDA-approved indications for fluoroquinolones in patients under 18 years are limited to complicated urinary tract infections and pyelonephritis 2
Safety Concerns in Pediatric Patients
- Fluoroquinolones cause arthropathy in juvenile animals, which was the original basis for restricting their use in children 2, 3
- Clinical studies show higher rates of musculoskeletal adverse events in children receiving fluoroquinolones compared to control groups, with 9.3% of pediatric patients receiving ciprofloxacin experiencing musculoskeletal adverse events compared to 6.0% in control patients 4
Appropriate Use Guidelines
- The American Academy of Pediatrics suggests that fluoroquinolones should be considered only in the following circumstances: infections caused by multidrug-resistant pathogens with no alternative effective therapy 1, 2, 3
- Specific clinical scenarios that may warrant fluoroquinolone use include complicated urinary tract infections caused by P. aeruginosa or other multidrug-resistant gram-negative bacteria 4
Contraindications and Precautions
- Absolute contraindications for fluoroquinolone use include history of hypersensitivity to fluoroquinolones 3
- Relative contraindications include myasthenia gravis due to risk of exacerbation 3
Monitoring Recommendations
- When fluoroquinolones must be used in children, consider ECG monitoring in patients with cardiac risk factors or those taking other QT-prolonging medications 3